BridgeBio Q1 rev $194.5M, Attruby sales $180.6M; $500M share buyback authorized

BridgeBio Pharma, Inc.

2026-Q1 EPS reported -$0.84 vs consensus -$0.69 ▼ miss (-21.4%)

Q1 2026 total revenues net $194.5M, up from $116.6M YoY; Attruby U.S. net product revenue $180.6M.
Net loss attributable to common stockholders $164.0M ($0.84 per share), vs $167.4M ($0.88) in Q1 2025.
Cash, equivalents & marketable securities $940.2M as of March 31, 2026, up from $587.5M at Dec 31.
Board authorized $500M stock repurchase program; buybacks may occur open market or privately.
Submitted NDA for BBP-418 (LGMD2I/R9) to FDA; encaleret NDA planned 1H 2026; infigratinib NDA Q3 2026.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BridgeBio Pharma, Inc. reported the first quarter ended March 31, 2026 results: revenue $194.5 million.

Period: the first quarter ended March 31, 2026
Revenue: $194.5 million
Result: reported results

Exact text from the filing

except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates - $194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001743881-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.